Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medartis Holding AGXSWX:MED -1.43%85 EV-to-EBIT is 61.06 as of Jul. 19, 2026, which is 41% below its 10-year median of 103.52. GuruFocus rates XSWX:MED with a GF Score™ of 85/100 and a GF Value™ of CHF107.43 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Medartis Holding AG ranks worse than 89.68% on this metric.
The historical rank and industry rank for Medartis Holding AG's EV-to-EBIT or its related term are showing as below:
XSWX:MED'
s EV-to-EBIT Range Over the Past 10 Years
Min: -594.74 Med: 103.52 Max: 419.05
Current: 61.06
During the past 12 years, the highest EV-to-EBIT of Medartis Holding AG was 419.05. The lowest was -594.74. And the median was 103.52.
XSWX:MED's EV-to-EBIT is ranked worse than 89.68% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.43
vs XSWX:MED: 61.06
Medartis Holding AG (XSWX:MED) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Medartis Holding AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF1,221.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medartis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF20.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medartis Holding AG EV-to-EBIT Related Terms
Medartis Holding AG EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Medartis Holding AG's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medartis Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medartis Holding AG EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medartis Holding AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Medartis Holding AG's EV-to-EBIT falls into.
Medartis Holding AG's current Enterprise Value is CHF1,237.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medartis Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was CHF20.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medartis Holding AG (XSWX:MED) has a EV-to-EBIT of 61.06 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medartis Holding AG and its competitors. This is 41% below median its historical median of 103.52. According to the industry distribution chart, Medartis Holding AG ranks #417 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 89.7%.
Is Medartis Holding AG's EV-to-EBIT too high?
Medartis Holding AG's current EV-to-EBIT of 61.06 is 41% below median its 10-year median of 103.52. The Medical Devices & Instruments industry median EV-to-EBIT is 18.43. Medartis Holding AG's value of 61.06 is 231.3% above this industry median. Based on the distribution chart, Medartis Holding AG ranks #417 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medartis Holding AG has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medartis Holding AG's EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medartis Holding AG ranks #417 out of 465 companies for EV-to-EBIT. This places Medartis Holding AG in the lower half of its industry. The industry median EV-to-EBIT is 18.43. Medartis Holding AG's value of 61.06 is 231.3% above this benchmark. While the company's 10-year median is 103.52 vs. the industry median of 18.43, Medartis Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.43, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medartis Holding AG's current EV-to-EBIT of 61.06 is 231.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Medartis Holding AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medartis Holding AG's current EV-to-EBIT is 61.06, which is 41% below median its own 10-year median of 103.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medartis Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Medartis Holding AG (XSWX:MED) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF107.43, compared to a current price of CHF89.40 — trading 16.8% below its estimated fair value. The current EV-to-EBIT is 61.06, which is 41% below median its 10-year median of 103.52 and 231.3% above the Medical Devices & Instruments industry median of 18.43. Medartis Holding AG's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Medartis Holding AG (XSWX:MED), the current EV-to-EBIT is 61.06 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medartis Holding AG (XSWX:MED) Overvalued in 2026?
Based on GuruFocus' analysis, Medartis Holding AG stock appears to be undervalued.
The current stock price of CHF89.40 is trading 16.8% below its estimated GF Value™ of CHF107.43.
GuruFocus considers Medartis Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:MED:
EV-to-EBIT: 61.06 (41% below median its 10-year median of 103.52)
GF Value™: CHF107.43 vs. price of CHF89.40 (16.8% below fair value)
Industry Position: 231.3% above the Medical Devices & Instruments median (#417 of 465)
No single metric tells the full story. See the XSWX:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medartis Holding AG is a medical device company. The company's product profile is divided into APTUS products, StealthFix Products, and MODUS products. APTUS includes products for the Hand, Wrist, Elbow, Shoulder, and Foot. MODUS comprises products for the mandible. Geographically, it derives the majority of its revenue from Europe, Middle East and Africa (EMEA) and also has a presence in North America, Asia Pacific, and Latin America.
85GF Score
Get the complete analysis for XSWX:MED
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MED has been successfully added to your 
